A Study of Viracept in AIDS Patients With Mycobacterium Avium Complex Disease (MAC)

Agouron Pharmaceuticals

Status and phase: Completed; Phase 2

Conditions: Mycobacterium Avium-Intracellulare Infection; HIV Infections

Treatments: Drug: Nelfinavir mesylate

Study type: Interventional

Funder types: Industry

Identifiers

NCT00002170

Study 518

259C

AG1343-518

Details and patient eligibility

About

The purpose of this study is to see if it is safe and effective to give Viracept to AIDS patients who are being treated for MAC.

Sex: All

Ages: 13+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

Patients must have:

• HIV infection
• New diagnosis of MAC bacteremia and < 7 days of therapy.

Prior Medication:

Allowed:

Patients no more than 7 days of therapy for MAC disease.

Exclusion Criteria

Prior Medication:

Excluded:

Prior therapy (or less than 2 weeks) with protease inhibitors other than saquinavir.